Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its price target boosted by Chardan Capital from $88.00 to $91.00 in a research report released on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also issued reports on NTLA. JPMorgan Chase & Co. cut their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer cut their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. Robert W. Baird cut their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Royal Bank of Canada reissued an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, Wedbush reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.88.

Intellia Therapeutics Trading Up 1.4 %

NTLA opened at $14.17 on Monday. Intellia Therapeutics has a twelve month low of $13.54 and a twelve month high of $34.87. The company has a fifty day moving average of $18.64 and a 200-day moving average of $22.04.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same quarter last year, the company earned ($1.38) earnings per share. The company’s quarterly revenue was down 24.1% compared to the same quarter last year. As a group, analysts forecast that Intellia Therapeutics will post -5.13 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. First Horizon Advisors Inc. increased its holdings in Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the last quarter. Elmwood Wealth Management Inc. increased its holdings in Intellia Therapeutics by 0.9% during the third quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock worth $1,393,000 after buying an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares during the last quarter. Capstone Investment Advisors LLC increased its holdings in Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after buying an additional 831 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its holdings in Intellia Therapeutics by 6.5% during the first quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after buying an additional 1,010 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.